Xencor (XNCR) Competitors $19.24 -0.79 (-3.94%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XNCR vs. CYTK, NUVL, GRFS, AXSM, VKTX, TGTX, KRYS, OGN, SRRK, and ALVOShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Axsome Therapeutics (AXSM), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), Organon & Co. (OGN), Scholar Rock (SRRK), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Cytokinetics Nuvalent Grifols Axsome Therapeutics Viking Therapeutics TG Therapeutics Krystal Biotech Organon & Co. Scholar Rock Alvotech Xencor (NASDAQ:XNCR) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Does the MarketBeat Community favor XNCR or CYTK? Cytokinetics received 303 more outperform votes than Xencor when rated by MarketBeat users. Likewise, 79.78% of users gave Cytokinetics an outperform vote while only 73.44% of users gave Xencor an outperform vote. CompanyUnderperformOutperformXencorOutperform Votes50673.44% Underperform Votes18326.56% CytokineticsOutperform Votes80979.78% Underperform Votes20520.22% Which has preferable earnings and valuation, XNCR or CYTK? Xencor has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$168.34M8.00-$126.09M-$3.20-6.01Cytokinetics$3.22M1,676.91-$526.24M-$5.38-8.50 Which has more risk & volatility, XNCR or CYTK? Xencor has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Is XNCR or CYTK more profitable? Xencor has a net margin of -232.77% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Xencor's return on equity.Company Net Margins Return on Equity Return on Assets Xencor-232.77% -30.92% -21.74% Cytokinetics -17,906.25%N/A -50.21% Do analysts prefer XNCR or CYTK? Xencor currently has a consensus price target of $36.56, suggesting a potential upside of 90.00%. Cytokinetics has a consensus price target of $83.64, suggesting a potential upside of 82.87%. Given Xencor's stronger consensus rating and higher possible upside, research analysts plainly believe Xencor is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to XNCR or CYTK? In the previous week, Cytokinetics had 9 more articles in the media than Xencor. MarketBeat recorded 13 mentions for Cytokinetics and 4 mentions for Xencor. Xencor's average media sentiment score of 0.53 beat Cytokinetics' score of 0.52 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryXencor beats Cytokinetics on 10 of the 17 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.35B$6.58B$5.36B$9.11BDividend YieldN/A2.95%5.13%4.03%P/E Ratio-6.019.8389.4717.33Price / Sales8.00307.311,263.57137.15Price / CashN/A61.4443.7535.97Price / Book1.756.055.324.80Net Income-$126.09M$154.62M$122.60M$224.91M7 Day Performance-6.60%-1.68%0.69%1.77%1 Month Performance-23.16%-2.35%1.55%2.22%1 Year Performance-3.85%1.02%27.25%20.67% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor4.2139 of 5 stars$19.24-3.9%$36.56+90.0%-3.8%$1.35B$168.34M-6.01280CYTKCytokinetics4.313 of 5 stars$46.69+0.2%$83.64+79.1%-46.6%$5.51B$7.53M-8.68250Analyst ForecastNUVLNuvalent1.793 of 5 stars$72.09-5.9%$112.36+55.9%+2.7%$5.12BN/A-20.7840Analyst ForecastInsider TradeNews CoverageGRFSGrifols2.0473 of 5 stars$7.21-1.1%N/A+7.2%$4.96B$7.01B5.9126,300Positive NewsGap DownAXSMAxsome Therapeutics4.6334 of 5 stars$89.15+11.4%$129.43+45.2%+7.5%$4.32B$338.46M-13.65380Analyst RevisionGap UpVKTXViking Therapeutics3.922 of 5 stars$38.76-1.4%$106.75+175.4%+52.4%$4.32BN/A-41.6820Analyst ForecastGap DownTGTXTG Therapeutics4.4921 of 5 stars$27.71-4.1%$40.67+46.8%+93.1%$4.31B$264.79M-277.07290Analyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.8312 of 5 stars$149.79-2.0%$206.67+38.0%+17.8%$4.31B$241.52M84.63229Short Interest ↓OGNOrganon & Co.4.8105 of 5 stars$15.63-1.4%$21.33+36.5%-0.8%$4.03B$6.41B3.1010,000Positive NewsSRRKScholar Rock3.1277 of 5 stars$42.66+5.4%$40.43-5.2%+176.7%$3.99B$33.19M-18.15140Positive NewsALVOAlvotech2.552 of 5 stars$13.22-2.2%$18.00+36.2%+7.4%$3.99B$391.87M-7.151,026Positive News Related Companies and Tools Related Companies Cytokinetics Alternatives Nuvalent Alternatives Grifols Alternatives Axsome Therapeutics Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives Organon & Co. Alternatives Scholar Rock Alternatives Alvotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XNCR) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
